secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2025-06-30T23:59:59+00:00
Accession:  0001213900-25-059289
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna Therapeutics appoints Marc Grasso as CFO; Ryan Jones moves to advisor
-----------------------------------------------------------------------------

- Dr. Marc Grasso appointed CFO effective June 30, 2025; previously CFO of Alector (ALEC) and Kura Oncology (KURA).
- Outgoing CFO Ryan Jones will serve as strategic advisor through August 8, 2025; receives severance including 9 months salary and continued vesting.
- Grasso receives base salary of $510,000, sign-on bonus of $250,000, and option for 450,000 shares vesting over four years.
- Grasso brings over 25 years of experience in public company finance and biotech investment banking.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000121390025059289/0001213900-25-059289-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000121390025059289/ea0247451-8k_kyverna.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-059289

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer